NASDAQ: CMMB
Chemomab Therapeutics Ltd Stock Ownership - Who owns Chemomab Therapeutics?

Insider buying vs selling

Have Chemomab Therapeutics Ltd insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Neil Harris CohenDirector2026-08-281,000$2.80
$2.80kSell
Neil Harris CohenDirector2026-08-271,304$2.85
$3.72kSell
George Adi MorChief Executive Officer2026-05-294,878$2.05
$10.00kBuy
George Adi MorChief Executive Officer2026-05-294,926$2.08
$10.25kBuy

1 of 1

CMMB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CMMB insiders and whales buy or sell their stock.

CMMB Shareholders

What type of owners hold Chemomab Therapeutics Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Access Industries Holdings LLC1.19%6,911,166$9.12MInsider
Gabriel Capital Management Ltd0.87%5,034,150$6.65MInsider
Orbimed Israel GP Ltd0.39%2,241,274$2.96MInsider
George Adi Mor0.19%1,091,698$1.44MInsider
Peter Thiel0.15%877,973$1.16MInsider
Dennison T. Veru0.07%396,540$523.43kInsider
Stephen P. Squinto0.01%47,938$63.28kInsider
Frank Haluska0.01%36,082$47.63kInsider
Neil Harris Cohen0.01%33,000$43.56kInsider
John Lawler0.00%20,000$26.40kInsider

1 of 3

CMMB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CMMB0.00%2.89%Net BuyingNet Selling
INTS0.04%3.87%Net Buying
INAB0.02%99.98%Net Buying
DARE0.01%99.99%
CURX0.01%99.99%

Chemomab Therapeutics Stock Ownership FAQ

Who owns Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ: CMMB) is owned by 0.00% institutional shareholders, 2.89% Chemomab Therapeutics insiders, and 97.11% retail investors. Access Industries Holdings LLC is the largest individual Chemomab Therapeutics shareholder, owning 6.91M shares representing 1.19% of the company. Access Industries Holdings LLC's Chemomab Therapeutics shares are currently valued at $9.12M.

If you're new to stock investing, here's how to buy Chemomab Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.